Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Dragonfly Therapeutics is a clinical-stage biotech developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system. These therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses. Our molecules are expected to be potent as single agents as well as in treatment combinations with existing cancer immunotherapies. Our scientific founders are major figures in cancer biology and immunology and have launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients. For more information, email info@dragonflytx.com.

Lek Pharmaceuticals dd, a subsidiary of Novartis AG, is a company headquartered in Ljubljana, Slovenia, that develops, manufactures and markets drugs and pharmaceutical products. Robert Ljoljo is the CEO, in this role since 2019. On November 21, 2002 Novartis AG acquired Lek Pharmaceuticals dd for $689.24 million.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Shanghai Newren Biomedical Technology Co., Ltd., established on 2019-06-24, Business scope includes technology development in the field of biomedical technology,technical consulting,technology transfer,Technical Services;laboratory equipment,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals),Sales of Class I Medical Devices;Business Consulting;account Serive. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.